LEADER 05291nam 2200661 450 001 9910138970203321 005 20230803220640.0 010 $a3-527-67527-2 010 $a3-527-67528-0 010 $a3-527-67529-9 035 $a(CKB)2550000001175582 035 $a(EBL)1583680 035 $a(SSID)ssj0001169450 035 $a(PQKBManifestationID)11777260 035 $a(PQKBTitleCode)TC0001169450 035 $a(PQKBWorkID)11153987 035 $a(PQKB)11370743 035 $a(OCoLC)868661795 035 $a(MiAaPQ)EBC1583680 035 $a(Au-PeEL)EBL1583680 035 $a(CaPaEBR)ebr10822329 035 $a(CaONFJC)MIL556868 035 $a(OCoLC)866839740 035 $a(EXLCZ)992550000001175582 100 $a20111102h20142014 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aTherapeutic Fc-fusion proteins /$fedited by Steven M. Chamow [and three others] 210 1$aWeinheim :$cWiley-VCH Verlag GmbH,$d[2014] 210 4$dİ2014 215 $a1 online resource (400 p.) 300 $aDescription based upon print version of record. 311 $a3-527-33317-7 311 $a1-306-25617-8 320 $aIncludes bibliographical references and index. 327 $aTherapeutic Fc-Fusion Proteins; Contents; Preface; List of Contributors; 1 Introduction: Antibody Structure and Function; 1.1 Introduction to Antibodies; 1.2 General Domain and Structure of IgG; 1.2.1 Structural Aspects Important for Fc Fusion(s); 1.2.1.1 Fc Protein-Protein Interactions; 1.2.1.2 Fc Glycosylation; 1.2.1.3 Hinge and Interchain Disulfide Bonds; 1.3 The Neonatal Fc Receptor; 1.3.1 FcRn Function and Expression; 1.3.2 Species Difference in FcRn; 1.3.3 Engineering to Modulate Pharmacokinetics; 1.3.3.1 Fc Engineering 327 $a1.3.3.2 Other Engineering Efforts to Modify PK of an IgG or Fc Fusion1.4 Introduction to FcgR- and Complement-Mediated Effector Functions; 1.4.1 Cell Lysis and Phagocytosis Mediation; 1.4.2 FcgR-Mediated Effector Functions; 1.4.2.1 FcgR Biology; 1.4.2.2 Expression Profiles; 1.4.2.3 Therapeutic Relevancy; 1.4.3 Complement; 1.4.3.1 C1q Biology; 1.4.3.2 Therapeutic Relevancy; 1.4.4 Modifying Effector Functions; 1.4.4.1 FcgR-Dependent Effector Function; 1.4.4.2 Engineering; 1.4.4.3 Glycoengineering; 1.4.4.4 Reducing and Silencing Effector Function; 1.5 Current Trends in Antibody Engineering 327 $a1.5.1 Bispecific1.5.2 Drug Conjugates; References; Part One: Methods of Production for Fc-Fusion Proteins; 2 Fc-Fusion Protein Expression Technology; 2.1 Introduction; 2.2 Expression Systems Used for Fc-Fusion Proteins; 2.2.1 Expression Using Mammalian Cell Lines; 2.2.1.1 Host Cells; 2.2.1.2 Codon Optimization; 2.2.1.3 Vectors; 2.2.1.4 Stable versus Transient Expression; 2.2.1.5 Viral Transduction and Transfection Methods; 2.2.2 Expression Using Prokaryotic Cells; 2.2.2.1 Vectors; 2.2.3 Expression Using Baculovirus/Insect Cells; 2.2.3.1 Host Cells; 2.2.3.2 Vectors 327 $a2.2.3.3 Additional Considerations2.3 Summary; References; 3 Cell Culture-Based Production; 3.1 Introduction; 3.2 Basic Aspects of Industrial Cell Culture; 3.2.1 The Central Role of the Production Cell Line; 3.2.2 Production Systems; 3.2.3 Production Mode: Fed-Batch or Perfusion?; 3.2.4 Scale-Up; 3.2.5 Raw Materials and Process Control; 3.2.6 How to Develop or Optimize a Culture Production Process for Fc-Fusion Molecules; 3.3 Speci.c Process Considerations for Fc-Fusion Molecules; 3.3.1 Product Quality Challenges; 3.3.2 Process Strategies and Process Parameters 327 $a3.3.2.1 Temperature and Misfolding3.3.2.2 Other Process Parameters; 3.3.2.3 Glycosylation; 3.4 Case Studies; 3.4.1 LTBr-Fc (Baminercept); 3.4.2 rFVIIIFc; 3.5 Conclusions; References; 4 Downstream Processing of Fc-Fusion Proteins; 4.1 Introduction and Overview of Fc-Fusion Proteins; 4.2 Biochemistry of Fc-Fusion Proteins; 4.3 Purification of Fc-Fusion Proteins from Mammalian Cells; 4.3.1 Platform Approaches for Downstream Purification; 4.3.2 Comparison of Protein A Chromatography, Viral Inactivation, and Polishing Steps; 4.4 Purification of Fc-Fusion Protein from Microbial Systems 327 $a4.5 Future Innovations in Fc-Fusion Protein Downstream Processing 330 $aEdited by three pioneers in the field, each with longstanding experience in the biotech industry, this is the first book to cover every step in the development and production of Fc-fusion proteins -- from choosing the right design on a molecular level to batch optimization during production to quality control. The whole of the second part is devoted to case studies detailing the most important commercially available products and includes a chapter on promising new developments for the future. An invaluable resource for professionals already working on Fc-fusion proteins and a must for 606 $aProteins$xTherapeutic use 606 $aProtein drugs 615 0$aProteins$xTherapeutic use. 615 0$aProtein drugs. 676 $a613.5 701 $aChamow$b Steven Mark$0882023 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910138970203321 996 $aTherapeutic Fc-fusion proteins$91970262 997 $aUNINA